Cargando…

Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up

PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pertz, Milena, Schlömer, Sabine, Seidel, Clemens, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Wick, Antje, Fliessbach, Klaus, Hoppe, Christian, Klingner, Marcel, Felsberg, Jörg, Reifenberger, Guido, Gramatzki, Dorothee, Weller, Michael, Schlegel, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522752/
https://www.ncbi.nlm.nih.gov/pubmed/37648934
http://dx.doi.org/10.1007/s11060-023-04419-y
_version_ 1785110421253914624
author Pertz, Milena
Schlömer, Sabine
Seidel, Clemens
Hentschel, Bettina
Löffler, Markus
Schackert, Gabriele
Krex, Dietmar
Juratli, Tareq
Tonn, Joerg Christian
Schnell, Oliver
Vatter, Hartmut
Simon, Matthias
Westphal, Manfred
Martens, Tobias
Sabel, Michael
Bendszus, Martin
Dörner, Nils
Wick, Antje
Fliessbach, Klaus
Hoppe, Christian
Klingner, Marcel
Felsberg, Jörg
Reifenberger, Guido
Gramatzki, Dorothee
Weller, Michael
Schlegel, Uwe
author_facet Pertz, Milena
Schlömer, Sabine
Seidel, Clemens
Hentschel, Bettina
Löffler, Markus
Schackert, Gabriele
Krex, Dietmar
Juratli, Tareq
Tonn, Joerg Christian
Schnell, Oliver
Vatter, Hartmut
Simon, Matthias
Westphal, Manfred
Martens, Tobias
Sabel, Michael
Bendszus, Martin
Dörner, Nils
Wick, Antje
Fliessbach, Klaus
Hoppe, Christian
Klingner, Marcel
Felsberg, Jörg
Reifenberger, Guido
Gramatzki, Dorothee
Weller, Michael
Schlegel, Uwe
author_sort Pertz, Milena
collection PubMed
description PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus on hippocampal irradiation. METHODS: Seventy-one glioma patients (WHO grade 1–4) were serially evaluated with neurocognitive testing and quality of life questionnaires. Prior to (baseline) and following further treatment (median 7.1 years [range 4.6–11.0] after baseline) a standardized computerized neurocognitive test battery (NeuroCog FX) was applied to gauge psychomotor speed and inhibition, verbal short-term memory, working memory, verbal and non-verbal memory as well as verbal fluency. Mean ipsilateral hippocampal radiation dose was determined in a subgroup of 27 patients who received radiotherapy according to radiotherapy plans to evaluate its association with neurocognition. RESULTS: Between baseline and follow-up mean performance in none of the cognitive domains significantly declined in any treatment modality (radiotherapy, chemotherapy, combined radio-chemotherapy, watchful-waiting), except for selective attention in patients receiving chemotherapy alone. Apart from one subtest (inhibition), mean ipsilateral hippocampal radiation dose > 50 Gy (Dmean) as compared to < 10 Gy showed no associations with long-term cognitive functioning. However, patients with Dmean < 10 Gy showed stable or improved performance in all cognitive domains, while patients with > 50 Gy numerically deteriorated in 4/8 domains. CONCLUSIONS: Multimodal glioma therapy seems to affect neurocognition less than generally assumed. Even patients with unilateral hippocampal irradiation with > 50 Gy showed no profound cognitive decline in this series. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04419-y.
format Online
Article
Text
id pubmed-10522752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-105227522023-09-28 Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up Pertz, Milena Schlömer, Sabine Seidel, Clemens Hentschel, Bettina Löffler, Markus Schackert, Gabriele Krex, Dietmar Juratli, Tareq Tonn, Joerg Christian Schnell, Oliver Vatter, Hartmut Simon, Matthias Westphal, Manfred Martens, Tobias Sabel, Michael Bendszus, Martin Dörner, Nils Wick, Antje Fliessbach, Klaus Hoppe, Christian Klingner, Marcel Felsberg, Jörg Reifenberger, Guido Gramatzki, Dorothee Weller, Michael Schlegel, Uwe J Neurooncol Research PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus on hippocampal irradiation. METHODS: Seventy-one glioma patients (WHO grade 1–4) were serially evaluated with neurocognitive testing and quality of life questionnaires. Prior to (baseline) and following further treatment (median 7.1 years [range 4.6–11.0] after baseline) a standardized computerized neurocognitive test battery (NeuroCog FX) was applied to gauge psychomotor speed and inhibition, verbal short-term memory, working memory, verbal and non-verbal memory as well as verbal fluency. Mean ipsilateral hippocampal radiation dose was determined in a subgroup of 27 patients who received radiotherapy according to radiotherapy plans to evaluate its association with neurocognition. RESULTS: Between baseline and follow-up mean performance in none of the cognitive domains significantly declined in any treatment modality (radiotherapy, chemotherapy, combined radio-chemotherapy, watchful-waiting), except for selective attention in patients receiving chemotherapy alone. Apart from one subtest (inhibition), mean ipsilateral hippocampal radiation dose > 50 Gy (Dmean) as compared to < 10 Gy showed no associations with long-term cognitive functioning. However, patients with Dmean < 10 Gy showed stable or improved performance in all cognitive domains, while patients with > 50 Gy numerically deteriorated in 4/8 domains. CONCLUSIONS: Multimodal glioma therapy seems to affect neurocognition less than generally assumed. Even patients with unilateral hippocampal irradiation with > 50 Gy showed no profound cognitive decline in this series. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11060-023-04419-y. Springer US 2023-08-30 2023 /pmc/articles/PMC10522752/ /pubmed/37648934 http://dx.doi.org/10.1007/s11060-023-04419-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Pertz, Milena
Schlömer, Sabine
Seidel, Clemens
Hentschel, Bettina
Löffler, Markus
Schackert, Gabriele
Krex, Dietmar
Juratli, Tareq
Tonn, Joerg Christian
Schnell, Oliver
Vatter, Hartmut
Simon, Matthias
Westphal, Manfred
Martens, Tobias
Sabel, Michael
Bendszus, Martin
Dörner, Nils
Wick, Antje
Fliessbach, Klaus
Hoppe, Christian
Klingner, Marcel
Felsberg, Jörg
Reifenberger, Guido
Gramatzki, Dorothee
Weller, Michael
Schlegel, Uwe
Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title_full Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title_fullStr Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title_full_unstemmed Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title_short Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
title_sort long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522752/
https://www.ncbi.nlm.nih.gov/pubmed/37648934
http://dx.doi.org/10.1007/s11060-023-04419-y
work_keys_str_mv AT pertzmilena longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT schlomersabine longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT seidelclemens longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT hentschelbettina longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT lofflermarkus longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT schackertgabriele longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT krexdietmar longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT juratlitareq longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT tonnjoergchristian longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT schnelloliver longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT vatterhartmut longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT simonmatthias longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT westphalmanfred longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT martenstobias longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT sabelmichael longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT bendszusmartin longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT dornernils longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT wickantje longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT fliessbachklaus longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT hoppechristian longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT klingnermarcel longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT felsbergjorg longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT reifenbergerguido longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT gramatzkidorothee longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT wellermichael longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT schlegeluwe longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup
AT longtermneurocognitivefunctionandqualityoflifeaftermultimodaltherapyinadultgliomapatientsaprospectivelongtermfollowup